Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2025 07:30 ET | Source: Novartis Pharma AG

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses

Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2 62% of patients treated with...
December 06, 2025 08:30 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Adaptive announces deep interventional use of clonoSEQ across abstracts at ASH
December 04, 2025 08:59 ET | Source: Parexel International LLC

Parexel Showcases Industry-Leading Hematology Expertise with Presentation of 10 Research Posters at the American Society of Hematology (ASH) Annual Meeting

RALEIGH, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life...
December 02, 2025 12:13 ET | Source: Quetzal Therapeutics

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
December 02, 2025 12:13 ET | Source: Quetzal Therapeutics

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
November 24, 2025 07:30 ET | Source: Adaptive Biotechnologies

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

Adaptive's clonoSEQ MRD Testing in Clinic and Research Settings Across ~90 Abstracts
November 18, 2025 09:07 ET | Source: Kyowa Kirin

Kyowa Kirin to Present New Research Highlighting Mogamulizumab’s Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting

Princeton, NJ, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new clinical study data spotlighting the potential...
October 22, 2025 11:57 ET | Source: Spherix Global Insights

Hemophilia Specialists Raise the Bar: Quality of Life and Innovation Drive Market Reordering

EXTON, PA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Hematologists across the United States are redefining what “success” looks like in hemophilia treatment, according to the latest findings from Market...
October 16, 2025 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML

Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
September 16, 2025 08:45 ET | Source: International Myeloma Foundation

The International Myeloma Foundation and IMF Nurse Leadership Board Inaugurate NLB Leadership and Mentorship Award

CLEVELAND, Ohio, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) and the IMF Nurse Leadership Board (NLB) proudly inaugurated and presented the first ever NLB...